4 D Molecular Therapeutics Inc (FDMT)

04:30 AM

What drives 4D Molecular Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia

04:30 AM

03:25 AM

4D Molecular Therapeutics Inc. Stock Analysis and ForecastTremendous portfolio expansion - PrintWeekIndia

03:25 AM

03:50 AM

Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionLong Term Secure Gain Stocks - Newser

03:50 AM

Jul 24, 2025

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists - GlobeNewswire

Jul 24, 2025

Jul 24, 2025

4DMT Reveals New Phase 2 Trial Results for Revolutionary Eye Disease Treatment at Major Conference - Stock Titan

Jul 24, 2025

Jul 23, 2025

What analysts say about 4D Molecular Therapeutics Inc. stockUnrivaled growth potential - Autocar Professional

Jul 23, 2025

Jul 23, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.56 Average Price Target from Analysts - Defense World

Jul 23, 2025

Jul 22, 2025

Is 4D Molecular Therapeutics Inc. a good long term investmentSignificant capital appreciation - jammulinksnews.com

Jul 22, 2025

Jul 19, 2025

Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace

Jul 19, 2025

Jul 18, 2025

Top Stocks for Aggressive Investors Top Growth StocksUnrivaled growth potential - Jammu Links News

Jul 18, 2025

Jul 18, 2025

Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech

Jul 18, 2025

Jul 17, 2025

4D Molecular Therapeutics’ Phase 3 Trial: A New Hope for Age-Related Macular Degeneration? - TipRanks

Jul 17, 2025

Jul 15, 2025

What makes 4D Molecular Therapeutics Inc. stock price move sharplyHigh Return Potential - Newser

Jul 15, 2025

Jul 15, 2025

How 4D Molecular Therapeutics Inc. stock performs during market volatilityAI Powered Stock Call - Newser

Jul 15, 2025

Jul 14, 2025

Weiss Ratings Reiterates “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 14, 2025

Jul 11, 2025

4DMT Announces New Employment Inducement Grants - GlobeNewswire

Jul 11, 2025

Jul 11, 2025

Late-Stage Biotech 4DMT Grants Significant RSU Package in Latest Strategic Hire - Stock Titan

Jul 11, 2025

Jul 10, 2025

4D Molecular to layoff about 25% of workforce - MSN

Jul 10, 2025

Jul 07, 2025

Promising Penny Stocks To Consider In July 2025 - simplywall.st

Jul 07, 2025

Jul 06, 2025

4D Molecular Therapeutics' (FDMT) Buy Rating Reiterated at Chardan Capital - MarketBeat

Jul 06, 2025

Jul 05, 2025

Chardan Capital Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 05, 2025

Jul 04, 2025

4D Molecular Therapeutics Analyst Ratings: A Comprehensive Analysis - AInvest

Jul 04, 2025

Jul 03, 2025

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Nasdaq

Jul 03, 2025

Jul 02, 2025

East Bay biotech to slash 25% of jobs after launching 2nd late-stage eye gene therapy study - The Business Journals

Jul 02, 2025

Jul 02, 2025

4D Molecular Therapeutics Accelerates Wet AMD Trial, Cuts Jobs to Offset Costs - MarketScreener

Jul 02, 2025

Jul 02, 2025

4DMT Announces Accelerated 4D-150 Phase 3 Development in - GlobeNewswire

Jul 02, 2025

Jul 02, 2025

4D Molecular to layoff about 25% of workforce (FDMT:NASDAQ) - Seeking Alpha

Jul 02, 2025

Jun 30, 2025

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell Microcap Growth Index - MarketScreener

Jun 30, 2025

Jun 28, 2025

Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jun 28, 2025

Jun 17, 2025

Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025

Jun 17, 2025

Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED

Jun 17, 2025

Jun 16, 2025

Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com

Jun 16, 2025

Jun 16, 2025

Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 16, 2025

Jun 13, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025

Jun 12, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Jun 12, 2025

Jun 12, 2025

908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World

Jun 12, 2025

Jun 12, 2025

Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World

Jun 12, 2025

Jun 12, 2025

Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World

Jun 12, 2025

Jun 11, 2025

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times

Jun 11, 2025